UGT1A1 and Hyperbilirubinemia: These findings are consistent with prior literature, which attributes atazanavir-associated hyperbilirubinemia to the inhibition of UDP-glucuronosyltransferase 1A1 (UGT1A1), a mechanism well-documented in protease inhibitor-based regimens [21].